Because clinical features of HER2-low breast cancer were profoundly influenced by HR status, therefore, the investigation of whether HER2-low tumors show a different mutation pattern compared to HER2-zero and HER2-positive tumors was also conducted within the HR+ and HR− subtypes. This evidence concerns the gene ERBB2 and breast cancer.